Oncology | CHOP Research Institute
 

Oncology

This study has several parts and involves taking a study drug called alpelisib.
Published on
Apr 12, 2024
This week, AACR names CHOP physician-scientists as grant recipients, and CIRP researchers publish new findings on driving and mood disorders.

The overall goal of this study is to find out if the study drug is safe and effective at treating adults and children with relapsed or refractory acute myeloid leukemia (R/R AML), high risk myelodysplastic syndrome (HR-MDS), or B-cell acute lymphoblastic leukemia (B-ALL).

This study enrolls patients that have been diagnosed with osteosarcoma or neuroblastoma that has come back (relapsed) or has not responded to standard treatments (refractory).
Published on
Mar 25, 2024
Rochelle Bagatell, MD, chaired the multidisciplinary panel that developed the NCCN guidelines, which will help to direct treatment of a highly heterogeneous disease.

This study has two parts. Part A enrolls patients who have been diagnosed with a solid tumor, lymphoma or desmoid tumor that has either come back ("relapsed") or does not respond to therapy ("is refractory").

This study enrolls patients that have been diagnosed with SMARCB1 or SMARCB4 deficient cancer that has either come back (“relapsed”) or does not respond to therapy (“is refractory”) or have been newly diagnosed with a SMARCB1 or SMARCB4 deficient cancer that has no known standard treatment.

This study involves taking the study drug, abatacept, by intravenous (IV) infusion.
Published on
Mar 5, 2024
Two global teams are developing solid cancer drugs and understanding T-cell receptors.

This study enrolls patients with newly diagnosed differentiated thyroid cancer (papillary thyroid cancer or follicular thyroid cancer) that has spread to the lungs and has a genetic mutation called and NTRK fusion.